Xinying Huang

Xinying Huang

Auto-generated profile, based on publicly available information

Xinying Huang

Capital Medical University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
ZHZhiwei Huang
Zhiwei Huang
JLJuncheng Lin
Juncheng Lin
ZCZuxin Cheng
Zuxin Cheng
MXMing Xu
Ming Xu
MGMingshu Guo
Mingshu Guo
JZJingui Zheng
Jingui Zheng
Panax japonicus C. A. Mey. is a rare traditional Chinese herbal medicine that uses ginsenosides as its main active ingredient. Rice does not produce ginsenosides because it lacks a key rate-limiting enzyme (β-amyrin synthase, βAS); however, it produces a secondary metabolite, 2,3-oxidosqualene, which is a precursor for ginsenoside biosynthesis. In the present study, the P. japonicus βAS gene was transformed into the rice cultivar ‘Taijing 9’ using an Agrobacterium-mediated approach, resulting in 68 rice transgenic plants of the T0 generation. Transfer-DNA (T-DNA) insertion sites in homozygous lines of the T2 generation were determined by using high-efficiency thermal asymmetric interlaced PCR (hiTAIL-PCR) and were found to vary among the tested lines. Approximately 1–2 copies of the βAS gene were detected in transgenic rice plants. Real-time PCR and Western blotting analyses showed that the transformed βAS gene could be overexpressed and β-amyrin synthase could be expressed in rice. HPLC analysis showed that the concentration of oleanane-type sapogenin oleanolic acid in transgenic rice was 8.3–11.5 mg/100 g dw. The current study is the first report on the transformation of P. japonicus βAS gene into rice. We have successfully produced a new rice germplasm, “ginseng rice”, which produces oleanane-type sapogenin.

29 January 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YWYachen Wang
Yachen Wang
XCXin Chai
Xin Chai
YWYueqing Wang
Yueqing Wang
XYXuejun Yin
Xuejun Yin
XHXinying Huang
Xinying Huang
GLGuangwei Li
Guangwei Li
Background: Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation. Despite this, there remains a significant gap in understanding the effectiveness of digital health for individuals with prediabetes, particularly in reducing T2DM incidence and reverting to normoglycemia. Objective: This study aimed to assess the effectiveness of different intervention modes of digital health, face-to-face, and blended interventions, particularly the benefits of digital health intervention, in reducing T2DM incidence and facilitating the reversion to normoglycemia in adults with prediabetes compared to the usual care. Methods: We conducted a comprehensive search in 9 electronic databases, namely MEDLINE, Embase, ACP Journal Club, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, Cochrane Methodology Register, Health Technology Assessment, and NHS Economic Evaluation Database through Ovid, from the inception to October 2024. This review included randomized controlled trials (RCTs) that studied the effectiveness of lifestyle interventions in adults with prediabetes. The overall intervention effect was synthesized using a random-effects model. The I² statistic was used to assess heterogeneity across the RCTs. We performed a subgroup analysis to explore the effectiveness of digital health, face-to-face, and blended interventions compared with the control group, which received usual care. Results: From an initial 7868 records retrieved from 9 databases, we identified 54 articles from 31 RCTs. Our analysis showed that face-to-face interventions demonstrated a significant 46% risk reduction in T2DM incidence (risk ratio [RR] 0.54, 95% CI 0.47-0.63; I²=43%; P<.001), and a 46% increase in the reversion to normoglycemia (RR 1.46, 95% CI 1.11-1.91; I²=82%; P=.006), when compared with the control group. On the other hand, digital health interventions, compared with the control group, were associated with a 12% risk reduction in T2DM incidence (RR 0.88, 95% CI 0.77-1.01; I²=0.6%; P=.06). Moreover, the blended interventions combining digital and face-to-face interventions suggested a 37% risk reduction in T2DM incidence (RR 0.63, 95% CI 0.49-0.81;I²<0.01%; P<.001) and an 87% increase in the reversion to normoglycemia (RR 1.87, 95% CI 1.30-2.69; I²=23%; P=.001). However, no significant effect on the reversal of prediabetes to normoglycemia was observed from the digital health interventions. Conclusions: Face-to-face interventions have consistently demonstrated promising effectiveness in both reductions in T2DM incidence and reversion to normoglycemia in adults with prediabetes. However, the effectiveness of digital health interventions in these areas has not been sufficiently proven. Given these results, further research is required to provide more definitive evidence of digital health and blended interventions in T2DM prevention in the future. Trial Registration: PROSPERO CRD42023414313; https://tinyurl.com/55ac4j4n

5 March 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
CZChengyi Zhang
Chengyi Zhang
YLYang Liu
Yang Liu
HZHuimin Zhu
Huimin Zhu
XHXinying Huang
Xinying Huang
CGCang Guo
Cang Guo
FSFu‐Dong Shi
Fu‐Dong Shi
Background: Acute ischemic stroke is a major cause of mortality and disability worldwide, with approximately 7.4% to 7.7% recurrence within the first 3 months. This study aimed to identify potential biomarkers for predicting stroke recurrence. Methods and Results: We conducted a nested case–control study using a hospital‐based cohort from the Third China National Stroke Registry selecting 214 age‐ and sex‐matched patients with ischemic stroke with hypertension and no history of diabetes or heart disease. Using data‐independent acquisition for discovery and multiple reaction monitoring for quantitative validation, we identified 26 differentially expressed proteins in large‐artery atherosclerosis (Causative Classification of Ischemic Stroke [CCS]1), 16 in small‐artery occlusion (CCS3), and 25 in undetermined causes (CCS5) among patients with recurrent stroke. In the CCS1 and CCS3 subgroups, differentially expressed proteins were associated with platelet aggregation, neuronal death/cerebroprotection, and immune response, whereas differentially expressed proteins in the CCS5 subgroup were linked to altered metabolic functions. Validated recurrence predictors included proteins associated with neutrophil activity and vascular inflammation (TAGLN2 [transgelin 2], ITGAM [integrin subunit α M]/TAGLN2 ratio, ITGAM/MYL9 [myosin light chain 9] ratio, TAGLN2/RSU1 [Ras suppressor protein 1] ratio) in the CCS3 subgroup and proteins associated with endothelial plasticity and blood–brain barrier integrity (ITGAM/MYL9 ratio and COL1A2 [collagen type I α 2 chain]/MYL9 ratio) in the CCS3 and CCS5 subgroups, respectively. Conclusions: These findings provide a foundation for developing a blood‐based biomarker panel, using causative classifications, which may be used in routine clinical practice to predict stroke recurrence.

1 April 2025 in Stroke
Verified
Journal Article
Closed access
XQXin Qiu
Xin Qiu
YJYingyu Jiang
Yingyu Jiang
HGHongqiu Gu
Hongqiu Gu
YJYong Jiang
Yong Jiang
XHXinying Huang
Xinying Huang
ZPZi-Xiao Li PhD
Zi-Xiao Li PhD
BACKGROUND: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is recommended for secondary prevention in patients with a minor stroke or transient ischemic attack. However, the effectiveness of DAPT can be significantly influenced by genetic variations. This study aimed to estimate the impact of multiple single-nucleotide polymorphisms across various genes on DAPT efficacy using polygenic risk score (PRS). METHODS: In this post hoc analysis, we included 2905 patients from the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events), which enrolled a total of 5170 patients in China between October 2009 and July 2012. The primary outcome was new stroke within 90 days. Sixteen single-nucleotide polymorphisms across 7 genes involved in clopidogrel metabolism were selected for PRS development. PRS were calculated by summing single-nucleotide polymorphisms from each individual. The Cox proportional-hazards regression model was utilized to estimate the hazard ratio (HR) and 95% CIs of PRS. The predictive value of PRS was estimated by C statistic and compared with a previously validated model. RESULTS: The elevated PRSs were associated with an increased risk of new stroke within 90 days ( P trend =0.01). The efficacy of DAPT versus aspirin alone in preventing 1-year composite vascular events was significantly different between patients with low (adjusted HR, 0.47 [95% CI, 0.31–0.71]) and high PRSs (adjusted HR, 0.84 [95% CI, 0.60–1.18]; P interaction =0.03). In patients receiving DAPT, higher PRSs were associated with increased risk of new stroke and composite vascular events at 90 days (adjusted HR per SD increase was 1.51 [95% CI, 1.15–1.99]) and at 1 year (adjusted HR per SD increase was 1.34 [95% CI, 1.08–1.67]). The C statistic for predicting 90-day new stroke using the PRS developed in this study was 0.57 (95% CI, 0.52–0.62), compared with 0.52 (95% CI, 0.48–0.55) for the ABCD-GENE score. CONCLUSIONS: Using PRS integrating multiple genes may enhance the precision of secondary prevention strategies for patients with minor stroke or transient ischemic attack in the short and long term. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00979589.

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
JXJiamin Xu
Jiamin Xu
XHXinyan Hu
Xinyan Hu
XHXinying Huang
Xinying Huang
QJQianmei Jiang
Qianmei Jiang
HCHaochen Chi
Haochen Chi
JJJing Jing
Jing Jing
Background: Frailty is a multidimensional geriatric syndrome characterized by reduced physiological reserve and is consistently associated with adverse outcomes in cardiovascular diseases. Frailty has also been linked to poor short‐term prognosis in cerebrovascular disease. However, its association with long‐term functional recovery and stroke recurrence remains insufficiently established in large prospective cohorts. Methods: We conducted a cohort study using data from the Impairment of Cognition and Sleep Study of the China National Stroke Registry III. Frailty was assessed at baseline using a deficit accumulation frailty index and categorized as robust, pre‐frail, or frail. Primary outcomes were 1‐year excellent functional outcome (modified Rankin Scale 0–1), favorable functional outcome (modified Rankin Scale 0–2), and stroke recurrence. Secondary outcomes were corresponding outcomes at 3 and 6 months. Associations were evaluated using multivariable logistic and Cox regression models. Results: Among 2396 patients, 65.3% were robust, 18.0% pre‐frail, and 16.7% frail. Increasing frailty severity was independently associated with lower odds of 1‐year excellent functional outcome (pre‐frail: odds ratio [OR], 0.6; 95% CI, 0.4–0.8; frail: OR, 0.2; 95% CI, 0.2–0.3; P for trend <0.001). Frail patients also had higher stroke recurrence risk (hazard ratio [HR], 1.90; 95% CI, 1.33–2.71) and lower likelihood of favorable functional outcome. Similar dose–response relationships were observed at 3 and 6 months, with consistent findings in sensitivity and subgroup analyses. Conclusions: Frailty is common after acute ischemic stroke and shows a strong, graded association with 1‐year functional recovery, supporting its potential value for long‐term prognostic stratification beyond age and comorbidity burden.

4 July 2024 in JMIR Preprints
Verified
Preprint
Open access
YWYachen Wang
Yachen Wang
XCXin Chai
Xin Chai
YWYueqing Wang
Yueqing Wang
XYXuejun Yin
Xuejun Yin
XHXinying Huang
Xinying Huang
GLGuangwei Li
Guangwei Li
BACKGROUND Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation. Despite this, there remains a significant gap in understanding the effectiveness of digital health for individuals with prediabetes, particularly in reducing T2DM incidence and reverting to normoglycemia. OBJECTIVE This study aimed to assess the effectiveness of different intervention modes of digital health, face-to-face, and blended interventions, particularly the benefits of digital health intervention, in reducing T2DM incidence and facilitating the reversion to normoglycemia in adults with prediabetes compared to the usual care. METHODS We conducted a comprehensive search in 9 electronic databases, namely MEDLINE, Embase, ACP Journal Club, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, Cochrane Methodology Register, Health Technology Assessment, and NHS Economic Evaluation Database through Ovid, from the inception to October 2024. This review included randomized controlled trials (RCTs) that studied the effectiveness of lifestyle interventions in adults with prediabetes. The overall intervention effect was synthesized using a random-effects model. The I² statistic was used to assess heterogeneity across the RCTs. We performed a subgroup analysis to explore the effectiveness of digital health, face-to-face, and blended interventions compared with the control group, which received usual care. RESULTS From an initial 7868 records retrieved from 9 databases, we identified 54 articles from 31 RCTs. Our analysis showed that face-to-face interventions demonstrated a significant 46% risk reduction in T2DM incidence (risk ratio [RR] 0.54, 95% CI 0.47-0.63; I²=43%; P<.001), and a 46% increase in the reversion to normoglycemia (RR 1.46, 95% CI 1.11-1.91; I²=82%; P=.006), when compared with the control group. On the other hand, digital health interventions, compared with the control group, were associated with a 12% risk reduction in T2DM incidence (RR 0.88, 95% CI 0.77-1.01; I²=0.6%; P=.06). Moreover, the blended interventions combining digital and face-to-face interventions suggested a 37% risk reduction in T2DM incidence (RR 0.63, 95% CI 0.49-0.81;I²<0.01%; P<.001) and an 87% increase in the reversion to normoglycemia (RR 1.87, 95% CI 1.30-2.69; I²=23%; P=.001). However, no significant effect on the reversal of prediabetes to normoglycemia was observed from the digital health interventions. CONCLUSIONS Face-to-face interventions have consistently demonstrated promising effectiveness in both reductions in T2DM incidence and reversion to normoglycemia in adults with prediabetes. However, the effectiveness of digital health interventions in these areas has not been sufficiently proven. Given these results, further research is required to provide more definitive evidence of digital health and blended interventions in T2DM prevention in the future. CLINICALTRIAL PROSPERO CRD42023414313; https://tinyurl.com/55ac4j4n